Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
Status:
Withdrawn
Trial end date:
2021-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of
lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in
adults hospitalized with COVID-19 pneumonia.
Phase:
Phase 1
Details
Lead Sponsor:
Shire
Collaborators:
Takeda Development Center Americas (TDCA) Takeda Development Center Americas, Inc.